Molecular subtype specific therapy in high grade serous ovarian cancer

高级别浆液性卵巢癌的分子亚型特异性治疗

• 批准号: nhmrc : 1081178
• 负责人: A/Pr Clare Scott
• 金额: $ 55.49万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/molecular-subtype-specific-ovarian-cancer/518790
• 关键词: Molecular; subtype; specific; therapy; grade

High grade serous ovarian cancer (HGSC) is the most common type of ovarian cancer, accounting for about two thirds of all deaths from the disease.Several years ago we identified distinct subtypes of HGSC (C1, C2, C4, C5) based on patterns of gene activity. We found that women with the C5 subtype generally had poor survival, and we mapped genes that were specifically active in C5 tumours. In this application we aim to develop therapies that are specifically targeted to the C5 HGSC.

高级别浆液性卵巢癌（High grade serous ovarian cancer，HGSC）是最常见的卵巢癌类型，约占该病死亡人数的三分之二。几年前，我们根据基因活性模式鉴定了HGSC的不同亚型（C1，C2，C4，C5）。我们发现C5亚型的女性通常生存率很低，我们绘制了在C5肿瘤中特别活跃的基因。在本申请中，我们的目标是开发特异性靶向C5 HGSC的疗法。